Cyclacel Pharmaceuticals (CYCC)
Create an AlertCYCC Key Stats
| Income Statement | |
| Revenue TTM | 0.401M |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -2.433 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -13.31M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -1454% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 33.62M |
| Enterprise Value | 19.49M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 3.286 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -5.46M |
| Return on Equity | -99.25% |
CYCC News
- 5 Stocks Insiders Love Right Now May 29
- Is It Now Time To Consider Cyclacel Pharmaceuticals? May 27
- Insiders at Lululemon and Restoration Hardware Sell Company Stock May 23
- Thursday 5/23 Insider Buying Report: SREV, CYCC May 23
- SMTC Corp Director Buys More Than 57K Shares and 4 Insider Trades to Note May 23
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vo... May 22
- Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering GlobeNewswire May 21
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial State... May 21
- Cyclacel Announces New Stock Issue May 16
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definit... May 16
CYCC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cyclacel Pharmaceuticals is down 4.04% over the last year vs S&P 500 Total Return up 23.89%, Alkermes up 73.74%, and 3SBio up 32.19%.
CYCC Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these CYCC related companies
Pro Ratings for CYCC
Pro Strategies Featuring CYCC
Did Cyclacel Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
CYCC Profile
Sector: Healthcare
Industry: Biotechnology
Other CYCC Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYCC | 3.09 | -0.03 | -0.96% | 33.62M |
